Showing results (91-100 of 118) with videos related to
Sort By:
Pageof 12
Bioorganic & Medicinal Chemistry Letters|March 10, 2004
Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidaseKeith G Watson, Rachel Cameron, Rob J Fenton, et al.ACS Medicinal Chemistry Letters|October 15, 2014
Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo ActivityZhi-Fu Tao, Lisa Hasvold, Le Wang, et al.Molecular Cell|November 18, 2017
Conversion of Bim-BH3 from Activator to Inhibitor of Bak through Structure-Based DesignJason M Brouwer, Ping Lan, Angus D Cowan, et al.Cell Reports|November 29, 2018
The Mitochondrial Apoptotic Effectors BAX/BAK Activate Caspase-3 and -7 to Trigger NLRP3 Inflammasome and Caspase-8 Driven IL-1β ActivationJames E Vince, Dominic De Nardo, Wenqing Gao, et al.Science Translational Medicine|August 4, 2017
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancerDelphine Merino, James R Whittle, François Vaillant, et al.Nature Communications|June 23, 2018
Conformational switching of the pseudokinase domain promotes human MLKL tetramerization and cell death by necroptosisEmma J Petrie, Jarrod J Sandow, Annette V Jacobsen, et al.Cell Reports|September 26, 2019
Viral MLKL Homologs Subvert Necroptotic Cell Death by Sequestering Cellular RIPK3Emma J Petrie, Jarrod J Sandow, Wil I L Lehmann, et al.Nature Communications|April 20, 2022
Development of NanoLuc-targeting protein degraders and a universal reporter system to benchmark tag-targeted degradation platformsChristoph Grohmann, Charlene M Magtoto, Joel R Walker, et al.Cell Death and Differentiation|April 9, 2025
Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro-survival BCL2 proteinsJia-Nan Gong, Tirta M Djajawi, Donia M Moujalled, et al.Chemmedchem|December 15, 2020
Synthesis and Biological Evaluation of (-) and (+)-Spiroleucettadine and AnaloguesMichael P Badart, Emma M Barnes, Andrew P Cording, et al.Pageof 12